TAC-001: A Toll-Like 9 Receptor Immune Agonist Conjugate for Solid Tumors
Time: 2:00 pm
day: Day Two
Details:
- Reviewing the scientific rationale behind TAC-001, a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22
- Outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors
- Exploring the potential of Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates
